Nivolumab - FOI Response Register

I am seeking to understand the initiation of patient treatment with Nivolumab and some additional products in different types of cancer. I would greatly appreciate if you could answer the following questions:

1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

•           Ipilimumab (monotherapy)

•           Nivolumab (monotherapy)                                   

•           Nivolumab AND Ipilimumab (combination)

•           Pembrolizumab

•           Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)

•           Other active systemic anti-cancer therapy   

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Zero

2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal cell carcinoma? 

•           Nivolumab (monotherapy)

•           Nivolumab + Ipilimumab                            

•           Nivolumab + Cabozantinib

•           Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. 

Zero

3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

•           Nivolumab monotherapy or in combination with Ipilimumab

•           Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

•           Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Zero